Login to Your Account

Second Verse Same as the First

Reata, Abbott Ink Another $400M Up-Front Deal

By Marie Powers
Staff Writer

Tuesday, December 13, 2011
A year after landing a $450-million up-front deal with Abbott for its lead antioxidant inflammation modulator (AIM) bardoxolone methyl, Reata Pharmaceuticals Inc. hit the rewind button, gaining another one-time $400 million license payment from the pharma giant to develop the rest of its second-generation AIM portfolio.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription